Lifeforce Capital — 2022 Investments
2 investments dated 2022 · listed companies and verified rows first · show all
64x provides a platform and product suite for manufacturing advanced therapeutics, including gene therapies, cell therapies, and biologics.
BiotechDeep TechMedical Devices
Co-investorsBoxGroupFifty YearsFirst Round CapitalFuture VenturesNorthpond VenturesRefactor Capital+1 more
64x develops infrastructure and manufacturing systems for next-generation medicines, focusing on genetic engineering, cell line development, and computational biology to enable scalability of advanced therapies.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesSan Francisco, US
Lexi Rovner(Co-founder & CEO)in
Co-investorsFifty YearsFuture VenturesRaptor GroupY CombinatorAlix VenturesBoxGroup+4 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.